As GLP-1 medications reshape appetite and eating behaviours, new nutritional risks and opportunities are emerging across the food and beverage sector. Drawing on insights from PortionIQ nutritionist Mark Gilbert, this feature examines how manufacturers, formulators and health stakeholders must respond to a rapidly evolving landscape.
This feature article is free to read.
